Daplusiran/Tomligisiran

N/A

Report date: 2026/02/19 20:00:18
NME

Base Information

Drug NameDaplusiran/Tomligisiran
Drug Alias NameJNJ-3989ARO-HBVJNJ-73763989GSK5637608GSK-5637608
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceHepatitis B virus capsid protein modulatorsAsialoglycoprotein receptor modulators
TargetsHepatitis B virus capsid proteinAsialoglycoprotein receptor
Therapy Area/IndicationsRenal InsufficiencyHepatitis D, ChronicHepatitis B, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsYes
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesArrowhead Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcXian Janssen Pharmaceutical LtdJanssen Sciences Ireland Uc +[4] 
Inactive CompaniesCompany Integrity Bio IncJanssen Sciences Ireland UnltdJohnson & Johnson (China) Investment Ltd +[5] 
Active IndicationsRenal InsufficiencyHepatitis D, ChronicHepatitis B, Chronic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A